regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
2025: Tristan Tan Yi Rui, who was originally condemned to death for trafficking not less than 337.6 grams of methamphetamine, later had his sentence commuted to life imprisonment after President Tharman Shanmugaratnam granted his clemency plea. This marked the first successful clemency plea in 27 years.
=== Migrations === White sharks go on vast migrations in response to food availability and temperature changes, as well as possibly to mate. One individual that was tagged off the South African coast swam to the southern coast of Australia and back within a year. Another white shark from South Africa was tracked swimming to Australia's northwestern coast and back, a journey of 20,000 km (12,000 mi; 11,000 nmi) in under nine months. In May 2024, a satellite tag was recovered from an Indonesian fisherman, which was determined to have come from a subadult female white shark tagged off the South African coast in May 2012, which swam to and was killed off the Indonesian coast in November 2016. In the northeastern Pacific, white sharks travel between the coastal US and Mexico and the Hawaiian Archipelago; they feed along the coast during fall and winter and farther out to sea during spring and summer. In the western North Atlantic, white sharks congregate between the Gulf of Maine and Cape Hatteras during spring and summer, and shift farther south toward Florida and into the Gulf of Mexico during the fall and winter. In fall, winter, and spring, some sharks disperse widely across the ocean, reaching as far east as the Azores.
Two-stroke chainsaws require about 2–5% of oil in the fuel to lubricate the engine, while the motor in electrical chain-saws is normally lubricated for life. Most modern gasoline-operated saws today require a fuel mix of 2% (1:50). Gasoline that contains ethanol can result in problems for the equipment because ethanol dissolves plastic, rubber, and other material. This leads to problems, especially on older equipment. A workaround for this problem is to run fresh fuel only and run the saw dry at the end of the work. Separate chain oil or bar oil is used for the lubrication of the bar and chain on all types of chainsaws. The chain oil is depleted because it tends to be thrown off by chain centrifugal force. On two-stroke chainsaws, the chain oil reservoir is usually filled up at the same time as refueling. The reservoir is normally large enough to provide sufficient chain oil between refueling. Lack of chain oil, or using an oil of incorrect viscosity, is a common source of damage to chainsaws, and tends to lead to rapid wear of the bar, or the chain seizing or coming off the bar. In addition to being quite thick, chain oil is particularly sticky (due to "tackifier" additives) to reduce the amount thrown off the chain. Although motor oil is a common emergency substitute, it is lost even faster, leaving the chain less lubricated. Oil is pumped from a small pump to a hole in the bar. From there, the lower ends of each chain drive link take a portion of the oil into the gauge towards the bar nose. The pump outlet and bar hole must be aligned.
Sources: en.wikipedia.org
In response to New York; 50 Cent took aim at both Fat Joe and Jadakiss for their collaboration with Ja Rule on the diss track "Piggy Bank" the following year with the release of his sophomore album The Massacre. Jadakiss responded with the track "Checkmate" six days later, While Fat Joe retaliated with the diss track "My Fofo" on his album All or Nothing three months later.
Because this process removes/inactivates the lipid coating of a virus, viruses without any sort of lipid envelope will be unaffected. There is also no inactivation effect by the buffers used in this process.
First explicitly noted in the 19th century by Claude Bernard who named it. Hormone a chemical released by one of the endocrine glands or tissues, and which has effects on other tissues. Insulin is a hormone as are glucagon, adrenaline, and angiotensin II. Human insulin Man-made insulins that is identical to the insulin produced by your own body. It is produced by bacteria which have had insulin genes installed into them. Human insulin has been available since October 1982. Genentech developed the first production mechanism. Hyperglycemia a condition in which glucose levels are higher than usual. Hyperinsulinism Too high a level of insulin in the blood. This often involves a condition in which the body produces too much insulin. Researchers believe that this condition may play a role in the development of noninsulin-dependent diabetes (or perhaps its side-effects) and in hypertension. See also: Syndrome X. Hyperlipemia See: Hyperlipidemia. Hyperlipidemia Too high a level of fats (lipids) in the blood. See also: Syndrome X. Hyperosmolar coma A coma (loss of consciousness) related to high levels of glucose (sugar) in the blood and requiring emergency treatment. A person with this condition is usually older and weak from loss of body fluids and weight. The person may or may not have a previous history of diabetes. Ketones (acids) are not typically present in the urine. Hypertension a condition in which blood pressure is higher than normal. See high blood pressure. Hypoglycemia a condition in which blood glucose levels are lower than normal.
Since 1991, the year the Gulf War ended, veterans and their families voiced concern about subsequent health problems. In 1999, an assessment of the first 1,000 veterans involved in the Ministry of Defence's Gulf War medical assessment programme found "no evidence" of a single illness, physical or mental, that would explain the pattern of symptoms observed in the group. In 1999, MEDACT petitioned for the WHO to conduct an investigation into illnesses in veterans and Iraqi civilians. A major 2006 review of peer-reviewed literature by a US Institute of Medicine (IOM) committee concluded that, "[b]ecause the symptoms vary greatly among individuals", they do not point to a syndrome unique to Gulf War veterans, though their report conceded that the lack of objective pre-deployment health data meant definitive conclusions were effectively impossible. Simon Wessely praised the IOM's review, and noted that, despite its central conclusion that no novel syndrome existed, its other findings made it "equally clear that service in the Gulf war did adversely affect health in some personnel". Aside from the lack of baseline data to guide analysis of the veterans' postwar health, because no detailed health screening was carried out when the veterans entered service, another major stumbling block with some studies, like the thousand-veteran one, is that the subjects are self-selected, rather than a random sample, making general conclusions impossible.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.